- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.06. | How Kardigan spun deal leftovers into a $400M IPO | 1 | BioPharma Dive | ||
| 23.06. | Kardigan, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.06. | Kardigan erzielt 460 Millionen US-Dollar bei Börsengang an der NASDAQ | 2 | Investing.com Deutsch | ||
| 22.06. | Kardigan closes $460 million IPO on Nasdaq | 1 | Investing.com | ||
| 22.06. | Kardigan, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | 240 | Business Wire | SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, Inc. (Nasdaq: KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root... ► Artikel lesen | |
| 18.06. | Kardigan's IPO Lands $400M for Drugs That Get to Root Causes of Heart Diseases | 1 | MedCity News | ||
| KARDIGAN Aktie jetzt für 0€ handeln | |||||
| 18.06. | Kardigan rises in Nasdaq debut after upsized $400 million IPO | 2 | Reuters | ||
| 18.06. | Kardigan rises on market debut after upsized IPO | 3 | Seeking Alpha | ||
| 18.06. | Heart drug biotech Kardigan raises $400m in upscaled IPO | 1 | pharmaphorum | ||
| 18.06. | Cardiovascular diseases biotech Kardigan prices upsized IPO at $16, the high end of the range | 2 | Renaissance Capital | ||
| 18.06. | Kardigan buttons up $400M upsized IPO to power heart drugs toward phase 3 | 3 | FierceBiotech | ||
| 18.06. | Cardiovascular biotech Kardigan prices upsized $400M IPO at $16/share | 1 | Seeking Alpha | ||
| 18.06. | Kardigan prices IPO at $16 per share, raising $400 million | 2 | Investing.com | ||
| 18.06. | Kardigan, Inc. Announces Pricing of Upsized Initial Public Offering | 277 | Business Wire | SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, Inc. (Nasdaq: KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root... ► Artikel lesen | |
| 17.06. | Kardigan, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 15.06. | Kardigan, Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 11.06. | Cardiology biotech Kardigan seeks up to $370M in U.S. IPO | 3 | Seeking Alpha | ||
| 11.06. | Cardiovascular diseases biotech Kardigan sets terms for $350 million IPO | 3 | Renaissance Capital | ||
| 11.06. | Heart drug developer Kardigan targets US$1.4 billion valuation in U.S. IPO | 1 | BNN Bloomberg | ||
| 11.06. | Phase 2b/3 cardiovascular diseases biotech Kardigan sets terms for $350 million IPO | 1 | Renaissance Capital |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 1,745 | -8,88 % | InnoCan Pharma vor kritischer Marke: 2,3% Verlust und das könnte erst der Anfang sein - Positionieren Sie sich vor Börseneröffnung | ||
| JAGUAR HEALTH | 2,290 | -0,87 % | Jaguar Health, Inc.: Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure | Company remains sharply focused on its ongoing global development program for crofelemer for rare IF diseasesNear-term milestones for IF program buttressed by continuing groundbreaking results of study... ► Artikel lesen | |
| KALA BIO | 1,180 | +0,43 % | XFRA 27F: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKALA BIO INC. O.N.... ► Artikel lesen | |
| IRONWOOD PHARMACEUTICALS | 3,840 | -2,04 % | IRONWOOD PHARMACEUTICALS INC - 8-K, Current Report | ||
| GALECTIN THERAPEUTICS | 3,700 | +3,93 % | Galectin Therapeutics Inc.: Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension | Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectinCompany intends to file the Phase 3 protocol in Q3 2026... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,455 | +0,20 % | Grace Therapeutics, Inc.: Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update | Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,540 | -0,15 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| MINDWALK | 1,260 | +0,80 % | MindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity | Inclusion in FTSE Russell's June 2026 semi-annual reconstitution expands visibility among institutional investors and broadens eligibility for index-tracking funds managing more than $12 trillion... ► Artikel lesen | |
| INMED PHARMACEUTICALS | 1,430 | 0,00 % | InMed Pharmaceuticals: InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4 | Vancouver, British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 2,525 | +0,60 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium | Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual... ► Artikel lesen | |
| LIPOCINE | 2,410 | 0,00 % | Lipocine Inc.: Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 | SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
| HERON THERAPEUTICS | 0,368 | -3,01 % | Heron Therapeutics, Inc.: U.S. District Court Issues Decision Regarding CINVANTI Patents | CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court... ► Artikel lesen | |
| HARROW | 36,400 | -9,00 % | Harrow, Inc.: Harrow Health, Inc. Announces Commercial Launch of BYOOVIZ in the United States | NASHVILLE, Tenn., July 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of... ► Artikel lesen | |
| INVENTIVA | 3,675 | 0,00 % | INVENTIVA: Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants | Daix (France), New York City (New York, United States), July 9, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| MEDICINOVA | 1,390 | 0,00 % | MediciNova, Inc.: MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment | LA JOLLA, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen |
KARDIGAN INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 24,550 Euro und damit -0,34 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KARDIGAN INC finden Sie auf Wallstreet Online.